#1 Clinical Trials Search in Europe

Ceritinib

Ceritinib is an investigational drug being studied in clinical trials for the treatment of various cancers, particularly those with genetic alterations in the anaplastic lymphoma kinase (ALK) gene. This article summarizes key information from several clinical trials evaluating ceritinib’s safety and efficacy in conditions like non-small cell lung cancer (NSCLC), hematologic malignancies, and other ALK-positive tumors.

Table of Contents

What is Ceritinib?

Ceritinib is a targeted cancer therapy drug. It is also known by the brand name Zykadia and the research code LDK378[1][2]. Ceritinib belongs to a class of medications called ALK inhibitors. ALK stands for Anaplastic Lymphoma Kinase, which is a protein that can become abnormal in some cancer cells and drive tumor growth[1].

How Ceritinib Works

Ceritinib works by blocking the activity of the abnormal ALK protein in cancer cells. By doing this, it can help slow down or stop the growth of tumors that are driven by ALK abnormalities. Ceritinib is considered a “targeted therapy” because it specifically targets cancer cells with ALK abnormalities, rather than affecting all rapidly dividing cells like traditional chemotherapy[3].

Conditions Treated with Ceritinib

Ceritinib is primarily used to treat certain types of cancers that have ALK abnormalities. These include:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. Ceritinib is approved for treating ALK-positive NSCLC[1][4].
  • ALK-positive tumors: This can include various types of cancers that have ALK abnormalities[3].
  • Brain metastases: Ceritinib is being studied for its effectiveness in treating cancer that has spread to the brain[5].

Research is ongoing to determine if ceritinib could be effective for other types of cancers, including:

  • Colorectal adenocarcinoma (a type of colon cancer)
  • Cholangiocarcinoma (bile duct cancer)
  • Pancreatic adenocarcinoma
  • Hepatocellular adenocarcinoma (a type of liver cancer)
  • Gastric adenocarcinoma (stomach cancer)
  • Esophageal adenocarcinoma[6]

How Ceritinib is Administered

Ceritinib is taken orally (by mouth) in the form of capsules or tablets. The typical dose is 750 mg once daily, though this may vary depending on the specific condition being treated and the patient’s response to the medication[4]. Some key points about taking ceritinib:

  • It is usually taken on an empty stomach, at least 1 hour before or 2 hours after a meal[3].
  • In some cases, it may be taken with a low-fat meal to reduce side effects[4].
  • For children or patients who have difficulty swallowing, the capsule contents can be mixed with a small amount of soft food[3].
  • Treatment typically continues until the disease progresses or side effects become unmanageable[7].

Effectiveness of Ceritinib

Clinical trials have shown that ceritinib can be effective in treating ALK-positive cancers, particularly in patients who have progressed on or are intolerant to other ALK inhibitors. Some measures of effectiveness include:

  • Overall Response Rate (ORR): This measures the percentage of patients whose cancer shrinks or disappears after treatment[5].
  • Progression-Free Survival (PFS): This is the length of time during and after treatment that a patient lives with the disease without it getting worse[2].
  • Duration of Response (DOR): This is how long the response to treatment lasts[5].

The exact effectiveness can vary depending on the specific type of cancer and the individual patient’s characteristics.

Potential Side Effects

Like all medications, ceritinib can cause side effects. Common side effects may include:

  • Gastrointestinal issues (diarrhea, nausea, vomiting)
  • Fatigue
  • Decreased appetite
  • Abdominal pain
  • Liver function abnormalities[4]

Your healthcare team will monitor you closely for side effects and may adjust your dose if needed.

Ongoing Research

Researchers continue to study ceritinib to understand its full potential. Some areas of ongoing research include:

  • Combining ceritinib with other medications: For example, a study is looking at combining ceritinib with trametinib for treating melanoma[8].
  • Using ceritinib in different types of cancers: Studies are exploring its use in cancers beyond lung cancer, such as thyroid cancer[7].
  • Optimizing dosing: Researchers are studying different dosing schedules and whether taking ceritinib with food can improve tolerability[4].

If you have questions about ceritinib or whether it might be appropriate for your condition, discuss this with your healthcare provider. They can provide personalized information based on your specific medical situation.

Aspect Details
Drug Name Ceritinib (also known as LDK378)
Main Target ALK (Anaplastic Lymphoma Kinase) positive cancers
Cancer Types Studied NSCLC, hematologic malignancies, thyroid cancer, other ALK+ solid tumors
Common Dosing 750 mg orally once daily (some trials testing lower doses)
Key Outcomes Measured Overall response rate, progression-free survival, safety/tolerability
Special Populations Studies include patients with brain metastases and pediatric patients
Ongoing Research Optimal dosing, efficacy in various ALK+ cancers, combination therapies

FAQ

  • What is ceritinib and how does it work? Ceritinib is an oral medication that inhibits the ALK protein. It is designed to target cancers that have genetic alterations in the ALK gene, which can drive tumor growth. By blocking ALK, ceritinib aims to slow or stop cancer progression.
  • What types of cancer is ceritinib being studied for? Ceritinib is being investigated for several cancer types, including ALK-positive non-small cell lung cancer (NSCLC), hematologic malignancies, thyroid cancer, and other solid tumors with ALK gene abnormalities.
  • How is ceritinib administered in clinical trials? In most trials, ceritinib is given orally once daily, often at a dose of 750 mg. Some studies are evaluating lower doses (450 mg or 600 mg) taken with food to improve tolerability.
  • What are some common side effects of ceritinib? While specific side effects are not detailed in the provided trial summaries, ALK inhibitors like ceritinib can commonly cause gastrointestinal effects, liver enzyme elevations, and fatigue. The trials are monitoring patients closely for adverse events.
  • How effective has ceritinib been in clinical trials so far? Several trials report promising results, including tumor responses and disease control in patients with ALK-positive cancers. However, effectiveness can vary depending on the specific cancer type and patient characteristics. More detailed results from completed trials are needed to fully assess ceritinib's efficacy.

Ongoing Clinical Trials on Ceritinib

  • Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study on Advanced Soft-Tissue Sarcoma: Testing Futibatinib and Drug Combination for Patients with Unresectable or Metastatic Conditions

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on Continued Ceritinib Treatment for Patients with ALK Positive Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Italy Poland

  • Study on Brigatinib, Ceritinib, and Alectinib for Patients with Advanced ALK+ Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • ALK (Anaplastic Lymphoma Kinase): A protein that, when altered, can promote cancer growth. Genetic changes in the ALK gene are found in some types of cancer.
  • NSCLC (Non-Small Cell Lung Cancer): A type of lung cancer that is the most common form of the disease, accounting for about 80-85% of all lung cancers.
  • Hematologic Malignancies: Cancers that affect blood, bone marrow, and lymph nodes. These include leukemias, lymphomas, and myelomas.
  • RECIST (Response Evaluation Criteria In Solid Tumors): A standardized way to measure how well a cancer patient responds to treatment, based on whether tumors shrink, stay the same, or get bigger.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent increasing the dose or require a dose reduction.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Leptomeningeal Carcinomatosis: A condition where cancer cells spread to the membranes (meninges) surrounding the brain and spinal cord.

References

  1. https://clinicaltrials.gov/study/NCT05100134
  2. https://clinicaltrials.gov/study/NCT02343679
  3. https://clinicaltrials.gov/study/NCT01742286
  4. https://clinicaltrials.gov/study/NCT02299505
  5. https://clinicaltrials.gov/study/NCT02336451
  6. https://clinicaltrials.gov/study/NCT02638909
  7. https://clinicaltrials.gov/study/NCT02289144
  8. https://clinicaltrials.gov/study/NCT03501368